We now live in a post-pandemic world. Covid-19 still exists but its impact on society alone has decreased. But for those who want to really protect themselves, the Covid-19 vaccine injection for the latest variant and also the flu is highly recommended, especially for high-risk groups. Moderna announced the success of a phase two trial of their combination Covid-19 and flu vaccine last week.
In phase two clinical trials, the mRNA-1083 vaccine showed an equivalent or better positive reaction compared to Fluarix flu vaccine, Fluzone HD and Moderna's Covod-19 Spikevax vaccine. Negative reactions to the vaccine were similar to other Covid-19 vaccines with only 4% showing grade three reactions classified as serious.
With the success of the second phase, the third phase test will start towards the end of 2023 with target mRNA-1083 being offered to the public by 2025.
Tags
SCIENCES